8-K: DT Cloud Acquisition Corporation Shareholders Approve Extension Amidst Significant Redemptions and New Shareholder Agreements

DT Cloud Acquisition Corporation's shareholders approved a reduction in the monthly extension fee and related amendments, while the company faced substantial share redemptions and entered into new voting agreements to retain capital for its business combination with Maius Pharmaceutical Co., Ltd.

Summary

• DT Cloud Acquisition Corporation (SPAC) held an Extraordinary General Meeting on May 23, 2025.
• Shareholders approved three key proposals: the Extension Fee Reduction Proposal, the Trust Amendment Proposal, and the Charter Amendment Proposal. The Adjournment Proposal was not presented due to sufficient votes for the other proposals.
• The Extension Fee Reduction Proposal amended the monthly fee payable by the sponsor into the trust account from $0.03 per unit to a fixed $60,000 for all outstanding Public Shares, effective May 23, 2025, until August 23, 2026, or earlier closing of a business combination.
• A quorum of 6,220,945 ordinary shares, representing approximately 91.92% of outstanding shares, was present at the meeting.
• Voting results for the Extension Fee Reduction Proposal were 4,394,958 For and 1,825,987 Against.
• Voting results for both the Trust Amendment Proposal and the Charter Amendment Proposal were 4,669,958 For and 1,550,987 Against.
• Holders of 3,872,314 ordinary shares exercised redemption rights, receiving approximately $10.69 per share, for an aggregate redemption amount of approximately $41,395,036.
• The SPAC and Maius Pharmaceutical Co., Ltd. (the target company) entered into Voting Agreements with certain shareholders.
• Under these agreements, shareholders who redeem 75% of their shares and forego redemption on the remaining 25% will receive two (2) additional rights (Additional SPAC Rights) for each non-redeemed share.
• Each seven (7) Additional SPAC Rights will entitle the holder to one ordinary share of the SPAC at the closing of the initial business combination, which will then convert into one ordinary share of Pubco (the surviving entity).

Sentiment

Score: 4

Explanation: The approval of the extension and related amendments is positive for the SPAC's ability to continue its business combination efforts. However, the very high redemption rate, leading to a significant reduction in trust account funds, and the need for special voting agreements to retain capital, indicate substantial challenges and a weakened financial position for the proposed merger. This suggests a moderately negative sentiment despite the procedural approvals.

Positives

• Shareholders approved the Extension Fee Reduction, Trust Amendment, and Charter Amendment proposals, indicating support for extending the business combination period.
• The reduction in the monthly extension fee from $0.03 per unit to a fixed $60,000 for all public shares could reduce the sponsor's financial burden, potentially making the extension more viable.
• The execution of Voting Agreements with certain shareholders aims to retain a portion of capital (25% of participating shareholders' holdings) by incentivizing them with additional rights, which could help meet minimum cash conditions for the business combination.
• The underlying Pubco shares from the Additional SPAC Rights will be registered on Form F-4 and traded on Nasdaq, providing liquidity for those shares post-combination.

Negatives

• A significant number of shares, 3,872,314 ordinary shares, were redeemed, representing approximately $41,395,036 in cash outflow, which substantially reduces the capital available in the trust account for the business combination.
• The high redemption rate indicates a lack of confidence from a large portion of shareholders in the proposed business combination or the SPAC's future.
• The need for Voting Agreements and the incentive of Additional SPAC Rights highlights the challenge in retaining shareholder capital and completing the business combination.
• The Additional SPAC Rights are not expected to be registered under the Securities Act of 1933 initially, which could limit their immediate transferability.

Risks

• The substantial redemptions significantly reduce the cash available in the trust account, potentially jeopardizing the ability to meet the minimum cash condition for the business combination with Maius Pharmaceutical Co., Ltd.
• The success of the business combination is contingent on the remaining capital and the effectiveness of the Voting Agreements in retaining sufficient funds.
• The Additional SPAC Rights are not registered under the Securities Act of 1933, which could pose regulatory risks or limit their liquidity until the underlying Pubco shares are registered on Form F-4.
• The "Most Favored Nation" clause in the Voting Agreement could obligate the SPAC to offer similar or better terms to other investors if more favorable agreements are made, potentially diluting the value of existing rights or increasing future obligations.
• The SPAC's ability to avoid being deemed an investment company under the Investment Company Act of 1940 is crucial, and its investment strategy for the trust account is designed to mitigate this risk.

Future Outlook

The company's future outlook is focused on successfully completing its initial business combination with Maius Pharmaceutical Co., Ltd. by August 23, 2026, or earlier. The approved extension fee reduction and the implementation of voting agreements are strategic measures to retain sufficient capital and facilitate the merger, despite significant recent share redemptions. The registration of Pubco ordinary shares underlying the Additional SPAC Rights on Form F-4 indicates an intention for these shares to be publicly traded post-combination.

Management Comments

• The SPAC intended to enter into voting agreements (the Voting Agreements) with certain shareholders of the SPAC.
• The Additional SPAC Rights are not expected to be registered under the Securities Act of 1933, as amended (the Securities Act).
• Each seven Additional SPAC Rights shall entitle the holder thereof to receive one ordinary share of the SPAC at the closing of an initial business combination, which in turn will be converted into one ordinary share of Pubco, the surviving entity of the contemplated business combination.
• The ordinary shares of Pubco underlying the Additional SPAC Rights will be registered on the Form F-4 registration statement under the Securities Act to be traded on Nasdaq upon the consummation of the contemplated business combination.

Industry Context

This filing is typical for a Special Purpose Acquisition Company (SPAC) nearing its deadline for a business combination. SPACs often face high redemption rates as their initial combination deadline approaches, especially in a challenging market environment or if the proposed target is not compelling enough for all initial investors. The strategy of reducing sponsor fees and offering incentives (additional rights) to retain capital is a common tactic employed by SPACs to ensure they meet the minimum cash requirements for their de-SPAC transaction. The high redemption rate seen here is consistent with a broader trend of increased redemptions in the SPAC market, making it harder for SPACs to close deals.

Comparison to Industry Standards

• The redemption rate of 3,872,314 shares out of 6,900,000 IPO units (assuming all units converted to shares) is very high, indicating a significant challenge in retaining capital. While specific industry benchmarks vary, redemption rates exceeding 50% are generally considered high and can complicate deal completion, with many SPACs in recent years experiencing rates well above 80%.
• The strategy of offering additional rights (warrants or similar instruments) to incentivize shareholders to not redeem is a common practice in the SPAC market, often referred to as "PIPE-like" arrangements or "backstop" agreements, used to shore up trust account balances.
• The reduction of the monthly extension fee from a per-unit basis to a fixed amount ($60,000) is a specific adaptation to the current market, potentially making the extension more palatable for the sponsor compared to the original $0.03 per unit, which could have been a much larger sum depending on the number of outstanding public shares.
• The target company, Maius Pharmaceutical Co., Ltd., suggests a focus on the biotechnology or pharmaceutical sector, an industry that has seen significant SPAC activity but also increased scrutiny and volatility.

Corporate Governance

Related Party Transactions

• The sponsor and/or its designee are responsible for paying the monthly extension fee into the trust account, which is a related party transaction. The fee structure has been amended.
• The Voting Agreements involve the SPAC, the target company (Maius Pharmaceutical Co., Ltd.), and certain shareholders, where shareholders receive Additional SPAC Rights for foregoing redemptions. This could be considered a related party transaction if the participating shareholders are also insiders or significant holders with influence.

Stakeholder Impact

• Shareholders: Those who redeemed shares received cash at approximately $10.69 per share. Those who participated in the Voting Agreements retained 25% of their shares and received additional rights, potentially benefiting from future upside if the business combination is successful. All shareholders are impacted by the extension of the combination period and the reduced sponsor contribution.
• Sponsor: Benefits from a reduced monthly extension fee, making it less costly to extend the combination period.
• Maius Pharmaceutical Co., Ltd. (Target Company): The success of the business combination is directly impacted by the amount of capital retained in the trust account. The Voting Agreements are designed to help ensure sufficient funds for the merger.
• Creditors: No direct impact mentioned, but the overall financial health and successful completion of the business combination could indirectly affect the company's creditworthiness.

Next Steps

• The SPAC must continue efforts to consummate its initial business combination with Maius Pharmaceutical Co., Ltd. by August 23, 2026.
• The SPAC will proceed with the terms of the Voting Agreements, issuing Additional SPAC Rights to participating shareholders.
• The Pubco ordinary shares underlying the Additional SPAC Rights will be registered on a Form F-4 registration statement for trading on Nasdaq upon the consummation of the business combination.

Key Dates

Recommendation

Keywords

SPAC, DT Cloud Acquisition Corporation, Maius Pharmaceutical Co., Ltd., Business Combination, Redemption, Extraordinary General Meeting, Extension Fee, Trust Account, Voting Agreement, Additional SPAC Rights, De-SPAC, Merger, Public Shares, Corporate Governance, SEC Filing, 8-K